Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy

International Journal of Clinical Oncology

Volumn 19, Issue 4, 2014, Pages 601-606

  Toyokawa, Gouji ^a   Takenoyama, Mitsuhiro ^a   Hirai, Fumihiko ^a   Toyozawa, Ryo ^a   Inamasu, Eiko ^a   Kojo, Miyako ^a   Morodomi, Yosuke ^a   Shiraishi, Yoshimasa ^a   Takenaka, Tomoyoshi ^a   Yamaguchi, Masafumi ^a   Shimokawa, Mototsugu ^a   Seto, Takashi ^a   Ichinose, Yukito ^a  

^a NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Gemcitabine; Malignant pleural mesothelioma; Second line treatment and beyond; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PEMETREXED; ANTINEOPLASTIC AGENT; ASBESTOS; DEOXYCYTIDINE; GLUTAMIC ACID DERIVATIVE; GUANINE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; JAPANESE (PEOPLE); LEUKOPENIA; LOSS OF APPETITE; MALE; MIDDLE AGED; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHLEBITIS; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CANCER STAGING; CHEMICALLY INDUCED; CLASSIFICATION; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLEURAL NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASBESTOS; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; VINBLASTINE;

EID: 84906355150     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0619-5     Document Type: Article

References (22)

1. Selikoff IJ, Churg J, Hammond EC (1965) Relation between exposure to asbestos and mesothelioma. N Engl J Med 272:560-565
2. Gemba K, Fujimoto N, Kato K et al (2012) National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci 103:483-490
3. Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022-1025
4. Ruffie P, Feld R, Minkin S et al (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 7:1157-1168 (Pubitemid 19196542)
5. Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54-63 discussion 63-5
6. Treasure T, Lang-Lazdunski L, Waller D et al (2011) Extrapleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763-772
7. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644 (Pubitemid 46606305)
8. Steele JP, Shamash J, Evans MT et al (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18:3912-3917
9. Stebbing J, Powles T, McPherson K et al (2009) The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 63:94-97
10. Byrne MJ, Davidson JA, Musk AW et al (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17:25-30 (Pubitemid 29022374)
11. Xanthopoulos A, Bauer TT, Blum TG et al (2008) Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study. J Occup Med Toxicol 3:34
12. Tan EH, Szczesna A, Krzakowski M et al (2005) Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49:233-240 (Pubitemid 40966752)
13. Rusch VW (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108:1122-1128
14. Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15:257-260 (Pubitemid 38262625)
15. Tsutani Y, Takuwa T, Miyata Y et al (2013) Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma. Ann Oncol Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 24:1005-1010
16. Ceresoli GL, Zucali PA, Gianoncelli L et al (2010) Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev 36:24-32
17. Maruyama R, Shoji F, Okamoto T et al (2005) Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma. Jpn J Clin Oncol 35:433-438 (Pubitemid 41309195)
18. Zucali PA, Ceresoli GL, Garassino I et al (2008) Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 112:1555-1561 (Pubitemid 351441168)
19. Kindler HL, Karrison TG, Gandara DR et al (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30:2509-2515
20. Nowak AK, Millward MJ, Creaney J et al (2012) A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol 7:1449-1456
21. Jackman DM, Kindler HL, Yeap BY et al (2008) Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113:808-814
22. Ramalingam SS, Belani CP, Ruel C et al (2009) Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 4:97-101